📊 RAPP Key Takeaways
Is Rapport Therapeutics, Inc. (RAPP) a Good Investment?
Rapport Therapeutics is an early-stage biopharmaceutical company with severely deteriorating fundamentals: $20M revenue generating -$24.2M operating losses and -$13.1M negative operating cash flow. While the balance sheet is solid with $471.5M equity and $78.1M cash providing ~6 years of runway at current burn rates, the company lacks meaningful revenue traction and profitability pathway, making it a speculative R&D-stage investment with significant execution risk and no proven commercial viability.
Rapport Therapeutics, Inc. Key Strengths (RAPP)
- Strong balance sheet with $471.5M stockholders equity and minimal leverage (0.00x debt-to-equity)
- Adequate cash reserves of $78.1M provides operational runway at current burn rate
- Exceptional liquidity position with 27.08x current ratio demonstrates short-term financial stability
- Modest improvement in per-share losses (EPS improved 24.3% YoY) suggests potential operational efficiency gains
RAPP Stock Risks: Rapport Therapeutics, Inc. Investment Risks
- Severe operating losses of -$24.2M against only $20M revenue indicate massive cash burn relative to revenue generation
- Negative operating cash flow of -$13.1M and -65.7% FCF margin shows inability to self-fund operations
- Early-stage biotech with unproven pipeline, no visibility into clinical success or regulatory approval timelines
- Significant runway depletion risk if development programs fail or burn rate accelerates beyond current -$13.1M annual pace
Key Metrics to Watch
- Quarterly operating cash flow and cash burn rate trajectory
- Clinical trial milestone achievements and regulatory filing progress
- Revenue growth and commercial revenue ramp from approved or near-approval products
- Cash runway sufficiency relative to major near-term development milestones
Rapport Therapeutics, Inc. (RAPP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 27.08x current ratio provides a solid financial cushion.
RAPP Profit Margin, ROE & Profitability Analysis
RAPP vs Healthcare Sector: How Rapport Therapeutics, Inc. Compares
How Rapport Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rapport Therapeutics, Inc. Stock Overvalued? RAPP Valuation Analysis 2026
Based on fundamental analysis, Rapport Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rapport Therapeutics, Inc. Balance Sheet: RAPP Debt, Cash & Liquidity
RAPP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rapport Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.78 indicates the company is currently unprofitable.
RAPP Revenue Growth, EPS Growth & YoY Performance
RAPP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$19.9M | $-0.42 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rapport Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
RAPP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rapport Therapeutics, Inc. (CIK: 0002012593)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RAPP
What is the AI rating for RAPP?
Rapport Therapeutics, Inc. (RAPP) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RAPP's key strengths?
Claude: Strong balance sheet with $471.5M stockholders equity and minimal leverage (0.00x debt-to-equity). Adequate cash reserves of $78.1M provides operational runway at current burn rate.
What are the risks of investing in RAPP?
Claude: Severe operating losses of -$24.2M against only $20M revenue indicate massive cash burn relative to revenue generation. Negative operating cash flow of -$13.1M and -65.7% FCF margin shows inability to self-fund operations.
What is RAPP's revenue and growth?
Rapport Therapeutics, Inc. reported revenue of $20.0M.
Does RAPP pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
Where can I find RAPP SEC filings?
Official SEC filings for Rapport Therapeutics, Inc. (CIK: 0002012593) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RAPP's EPS?
Rapport Therapeutics, Inc. has a diluted EPS of $-0.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RAPP's fundamental grade?
Based on our AI fundamental analysis in May 2026, Rapport Therapeutics, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RAPP stock overvalued or undervalued?
Valuation metrics for RAPP: ROE of -4.2% (sector avg: 15%), net margin of -99.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RAPP's AI grade for 2026?
Our dual AI analysis gives Rapport Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RAPP's free cash flow?
Rapport Therapeutics, Inc.'s operating cash flow is $-13.1M, with capital expenditures of $86.0K. FCF margin is -65.7%.
How does RAPP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -99.3% (avg: 12%), ROE -4.2% (avg: 15%), current ratio 27.08 (avg: 2).